Zobrazeno 1 - 10
of 131
pro vyhledávání: ''
Publikováno v:
Anti-Cancer Drugs. 33:e534-e540
We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the
Publikováno v:
Anti-Cancer Drugs. 32:1127-1130
Avapritinib is a tyrosine kinase inhibitor currently being investigated on clinical trials for the treatment of unresectable or metastatic gastrointestinal stromal tumour (GIST). It has been recently approved by the Food and Drug Administration and t
Autor:
Cuizhen Liu, Xinping Ye, Yanfeng Jiang, Guangzhi Zhu, Jing Tang, Tao Peng, Jie Ma, Zhiming Zeng, Jie Zeng, Fuchao Ma, Jinfeng Qiu, Lihua Yang
Publikováno v:
Anti-Cancer Drugs. 32:1093-1098
This study was to explore the efficacy and safety of camrelizumab combined with apatinib in patients with advanced liver cancer. Moreover, the relationship between peripheral blood parameters and tumor response rate was also investigated. Patients wi
Publikováno v:
Anti-Cancer Drugs. 31:959-965
After the failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy, some non-small cell lung cancer patients desire to receive switching with another EGFR-TKI (TKI-switching), although cytotoxic chemotherapy
Autor:
Andrea Vecchione, Paolo Palange, Giorgia Amira Osman, Valerio Giannelli, Daniele Remotti, Arnaldo Marra, Serena Ricciardi, Daniela Iacono, Alberto Ricci, Maria Rita Migliorino
Publikováno v:
Anti-Cancer Drugs. 30:757-761
In the last few years, immunotherapy has become part of everyday clinical practice for the treatment of many solid tumors including metastatic non-small-cell lung cancer. These drugs, however, can yield a specific toxicity profile that consists of im
Publikováno v:
Anti-Cancer Drugs. 30:179-185
In the pre-chemotherapy (CT) and post-CT settings of metastatic castration-resistant prostate cancer (mCRPC), abiraterone acetate plus prednisone (AAP) significantly extended median overall survival and radiographic progression-free survival (PFS) co
Autor:
Meng Qiu, Jing Zhang, Yuwen Zhou, Ye Chen, Feng Bi, Hong-Feng Gou, Dan Pu, Ji-Yan Liu, Bing Wu, Qiu Li
Publikováno v:
Anti-Cancer Drugs
Supplemental Digital Content is available in the text.
This study aimed to explore the correlation between survival and tumor calcification in patients with metastatic colorectal cancer who received cetuximab combined with chemotherapy. The stud
This study aimed to explore the correlation between survival and tumor calcification in patients with metastatic colorectal cancer who received cetuximab combined with chemotherapy. The stud
Publikováno v:
Anti-Cancer Drugs
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and is often discovered at an advanced stage with few therapeutic options. Current conventional regimens for PDA are associated with significant morbidity, decreased quality of life, and a
Autor:
Luana Lionetto, Lidia Strigari, Concetta Elisa Onesti, Serena Macrini, Antonella Petremolo, Francesca Di Pietro, Giovanna Gentile, Andrea Botticelli, Elisabetta Anselmi, Michela Roberto, Maurizio Simmaco, Rosa Falcone, Bruna Cerbelli, Paolo Marchetti, Federica Mazzuca, Annalisa Milano, Marina Borro, Mario Occhipinti
Publikováno v:
Anti-Cancer Drugs. 28:551-556
Fluoropyrimidines combined with other agents are commonly used for gastrointestinal cancer treatment. Considering that severe toxicities occur in 30% of patients, we aimed to structure a nomogram to predict toxicity, based on metabolic parameter and
Autor:
Philippe Aftimos, Andrea Varga, Jean-Charles Soria, Ahmad Awada, Sandrine Aspeslagh, Arturo A.S. Matos-Pita, Rastilav Bahleda
Publikováno v:
Anti-Cancer Drugs. 27:1021-1027
This phase I trial evaluated the toxicity profile and maximum tolerated dose of the combination between the marine derived cyclodepsipeptide plitidepsin and bevacizumab in advanced cancer patients. Thirteen patients were enrolled and treated with pli